ATTACHMENT A OHSU REF LAB PORTLAND VAMC 2..xlsx
XLSX spreadsheet 1 MB Posted
- Solicitation number
- 36C26026D0045
About this file
This is a pricing attachment for reference laboratory services awarded to Oregon Health & Science University under contract 36C26026D0045 for the Portland VA Medical Center. The attachment lists comprehensive laboratory test services organized by clinical discipline, including dermatology/pathology services, karyotyping and cytogenetics services, molecular genetic testing, and specialized oncology and hematology panels. The contract period runs from July 1, 2026 through June 30, 2027, with quantities specified for each line item in units of "each" (EA).
The pricing structure includes pre-discount unit prices and post-discount prices reflecting either 25% or 50% discounts depending on the service category. Dermatology services, such as immunohistochemistry and immunofluorescent studies, carry 50% discounts ranging from $31.50 to $559.00 pre-discount. The majority of cytogenetic and molecular services fall under the 25% discount tier, with pre-discount prices ranging from approximately $43.50 to $3,788.25, covering services such as chromosome analysis, microarray testing, gene sequencing panels, and specialized oncology/hematology diagnostic testing including panels for AML, CLL/SLL, multiple myeloma, and solid tumor analysis. The contract uses Clinical Laboratory Improvement Amendments (CLIA) test codes and includes both standard molecular testing and fluorescence in situ hybridization (FISH) methodologies, with separate pricing for fresh frozen tissue and formalin-fixed paraffin-embedded (FFPE) specimens where applicable.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| C03 36C26026D0045.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Action Line Item Information
| Action Type Name | Primary ID | Secondary ID | Mod Number | Title | Order Discount Type Name | Order Discount Type | Order Discount |
| Percent | 0 |
KB Version: FY25.08A
Items
| Vendor Test Code | SLIN | Test Name | REF CLIN | COMMENT | INCLUDE COMMENTS IN DOCUMENT | CONTRACT PERIOD | POP BEGIN | POP END | QUANTITY | UNIT OF MEASURE | PACKAGING MULTIPLE | RECEIPT TYPE | LINE ITEM IS | UNIT PRICE | ITEM DISCOUNT TYPE NAME | ITEM DISCOUNT | Lab Section | Price Pre discount | ADDRESS2 | ADDRESS3 | CITY | STATE | ZIP | ZIP4 | COUNTRY | MARK FRO | CONTACT NAME | CONTACT PHONE | CONTACT EMAIL | DDELIVERY DATE | FOB | SPECIAL INSTRUCTIONS | INCLUDE INSTRUCTIONS/COMMENTS IN DOCUMENT | INCLUDE DATA VALUES IN DOCUMENT | PRINCIPAL NAICS CODE | PRODUCT/SERVICE CODE | UNSPSC | SIC CODE | EAP# | NATIONAL STOCK NUMBER | LOCAL STOCK NUMBER | DM DOC ID | DELIVERY REF. COUNTER | UNIT TEXT/DESCRIPTION | DELIVERY REFERENCE | ITEM MASTER FILE NUMBER | EXPENDABLE/NON-EXPENDABLE | QUANTITY REQUESTED | UNIT OF PURCHASE CODE |
| DERM PATH SPECIAL STAINS GROUP 2 | 88313 | Yes | Base | 7/1/26 | 6/30/27 | 5 | EA | $ 234.00 | Percent | 50.00% | DERM | $ 468.00 | 621511 | Q301 | 80003508 | ||||||||||||||||||||||||||||||||||
| DERM PATH IMMUNOHISTOCHEMISTRY 1ST AB PER SPECIMEN | 88342 | Yes | Base | 7/1/26 | 6/30/27 | 5 | EA | $ 319.00 | Percent | 50.00% | DERM | $ 638.00 | 621511 | Q301 | 80003509 | ||||||||||||||||||||||||||||||||||
| DERM PATH IMMUNOFLUORESCENT STUDY DIRECT METHD | 88346 | Yes | Base | 7/1/26 | 6/30/27 | 15 | EA | $ 559.00 | Percent | 50.00% | DERM | $ 1,118.00 | 621511 | Q301 | 80003510 | ||||||||||||||||||||||||||||||||||
| HB DERM PATH REF CONSULT W/SLIDE PREP | 88323 | Yes | Base | 7/1/26 | 6/30/27 | 5 | EA | $ 68.00 | Percent | 50.00% | DERM | $ 136.00 | 621511 | Q301 | 80004058 | ||||||||||||||||||||||||||||||||||
| DERM MICROSLIDE CONSULT | 88321 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 31.50 | Percent | 50.00% | DERM | $ 63.00 | 621511 | Q301 | 80004058 | ||||||||||||||||||||||||||||||||||
| DERM PATH IMMUNOHISTOCHEMISTRY, EA ADDL SINGLE AB STAIN | 88341 | Yes | Base | 7/1/26 | 6/30/27 | 5 | EA | $ 86.00 | Percent | 50.00% | DERM | $ 172.00 | 621511 | Q301 | 80004199 | ||||||||||||||||||||||||||||||||||
| HB DERM PATH IADNA CANDIDA SPECIES AMPLIFIED PROBE TQ | 87481 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 187.50 | Percent | 25.00% | DERM | $ 250.00 | 621511 | Q301 | 80005768 | ||||||||||||||||||||||||||||||||||
| HB DERM IADNA HUMAN PAPILLOMAVIRUS HIGH-RISK TYPES | 87624 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 273.00 | Percent | 25.00% | DERM | $ 364.00 | 621511 | Q301 | 80005770 | ||||||||||||||||||||||||||||||||||
| HB DERM IADNA NOS AMPLIFIED PROBE TQ EACH ORGANISM | 87798 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 267.00 | Percent | 25.00% | DERM | $ 356.00 | 621511 | Q301 | 80005772 | ||||||||||||||||||||||||||||||||||
| 6020 | Amniotic Fluid: Full Chromosome Analysis | 88262 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 423.00 | Percent | 25.00% | KDL | $ 564.00 | 621511 | Q301 | 80001953 | |||||||||||||||||||||||||||||||||
| 6054 | Blood: High Resolution Chromosome Study reflexed to FISH | 88280 | Yes | Base | 7/1/26 | 6/30/27 | 4 | EA | $ 88.50 | Percent | 25.00% | KDL | $ 118.00 | 621511 | Q301 | 80001957 | |||||||||||||||||||||||||||||||||
| 6510 | Chromosome Microarray - Prenatal | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 165.75 | Percent | 25.00% | KDL | $ 221.00 | 621511 | Q301 | 80001958 | |||||||||||||||||||||||||||||||||
| 6242 | Fibroblast: Retrieval and Culture | 88233 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 478.50 | Percent | 25.00% | KDL | $ 638.00 | 621511 | Q301 | 80001960 | |||||||||||||||||||||||||||||||||
| 6242 | Fibroblast: Retrieval and Culture | 88233 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 478.50 | Percent | 25.00% | KDL | $ 638.00 | 621511 | Q301 | 80001960 | |||||||||||||||||||||||||||||||||
| 6080 | Breakage Analysis: Skin Chromosome Study | 88249 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 585.75 | Percent | 25.00% | KDL | $ 781.00 | 621511 | Q301 | 80001961 | |||||||||||||||||||||||||||||||||
| 6066 | Bone Marrow Chromosome Analysis | 88280 | Yes | Base | 7/1/26 | 6/30/27 | 49 | EA | $ 88.50 | Percent | 25.00% | KDL | $ 118.00 | 621511 | Q301 | 80001969 | |||||||||||||||||||||||||||||||||
| BONE MARROW SET UP | 88237 | Yes | Base | 7/1/26 | 6/30/27 | 7 | EA | $ 614.52 | Percent | 25.00% | KDL | $ 819.36 | 621511 | Q301 | 80001970 | ||||||||||||||||||||||||||||||||||
| 6300 | Hem/Onc Blood Chromosome Analysis | 88280 | Yes | Base | 7/1/26 | 6/30/27 | 3 | EA | $ 88.50 | Percent | 25.00% | KDL | $ 118.00 | 621511 | Q301 | 80001971 | |||||||||||||||||||||||||||||||||
| 6078 | Breakage Analysis: Blood Chromosome Study | 88249 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 585.75 | Percent | 25.00% | KDL | $ 781.00 | 621511 | Q301 | 80001974 | |||||||||||||||||||||||||||||||||
| 6080 | Breakage Analysis: Skin Chromosome Study | 88233 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 478.50 | Percent | 25.00% | KDL | $ 638.00 | 621511 | Q301 | 80001976 | |||||||||||||||||||||||||||||||||
| 1090 | Brugada Syndrome | 81406 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,093.50 | Percent | 25.00% | KDL | $ 1,458.00 | 621511 | Q301 | 80001976 | |||||||||||||||||||||||||||||||||
| 6620 | Premature Chromatid Separation Analysis | 88249 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 585.75 | Percent | 25.00% | KDL | $ 781.00 | 621511 | Q301 | 80001976 | |||||||||||||||||||||||||||||||||
| 6754 | Solid Tissue/Fibroblasts (includes POC): Full Chromosome Study reflexed to FISH | 88233 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 478.50 | Percent | 25.00% | KDL | $ 638.00 | 621511 | Q301 | 80001977 | |||||||||||||||||||||||||||||||||
| 6054 | Blood: High Resolution Chromosome Study reflexed to FISH | 88230 | Yes | Base | 7/1/26 | 6/30/27 | 4 | EA | $ 260.25 | Percent | 25.00% | KDL | $ 347.00 | 621511 | Q301 | 80001979 | |||||||||||||||||||||||||||||||||
| 6066 | Bone Marrow Chromosome Analysis | 88262 | Yes | Base | 7/1/26 | 6/30/27 | 49 | EA | $ 423.00 | Percent | 25.00% | KDL | $ 564.00 | 621511 | Q301 | 80001979 | |||||||||||||||||||||||||||||||||
| 6300 | Hem/Onc Blood Chromosome Analysis | 88262 | Yes | Base | 7/1/26 | 6/30/27 | 3 | EA | $ 423.00 | Percent | 25.00% | KDL | $ 564.00 | 621511 | Q301 | 80001979 | |||||||||||||||||||||||||||||||||
| 6810 | Solid Tissue Tumor: Full Study | 88280 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 88.50 | Percent | 25.00% | KDL | $ 118.00 | 621511 | Q301 | 80001979 | |||||||||||||||||||||||||||||||||
| 6754 | Solid Tissue/Fibroblasts (includes POC): Full Chromosome Study reflexed to FISH | 88280 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 88.50 | Percent | 25.00% | KDL | $ 118.00 | 621511 | Q301 | 80001979 | |||||||||||||||||||||||||||||||||
| 6460 | Solid Tissue/Lymph Node | 88280 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 88.50 | Percent | 25.00% | KDL | $ 118.00 | 621511 | Q301 | 80001979 | |||||||||||||||||||||||||||||||||
| 6750 | Solid Tissue/Spleen | 88280 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 88.50 | Percent | 25.00% | KDL | $ 118.00 | 621511 | Q301 | 80001979 | |||||||||||||||||||||||||||||||||
| 6750 | Tissue Chromosome Study | 88280 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 88.50 | Percent | 25.00% | KDL | $ 118.00 | 621511 | Q301 | 80001979 | |||||||||||||||||||||||||||||||||
| 6054 | Blood: High Resolution Chromosome Study reflexed to FISH | 88262 | Yes | Base | 7/1/26 | 6/30/27 | 4 | EA | $ 423.00 | Percent | 25.00% | KDL | $ 564.00 | 621511 | Q301 | 80001985 | |||||||||||||||||||||||||||||||||
| 6066 | Bone Marrow Chromosome Analysis | 88237 | Yes | Base | 7/1/26 | 6/30/27 | 49 | EA | $ 426.75 | Percent | 25.00% | KDL | $ 569.00 | 621511 | Q301 | 80001989 | |||||||||||||||||||||||||||||||||
| 1085 | Bone Marrow Failure Panel | 81406 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,749.75 | Percent | 25.00% | KDL | $ 2,333.00 | 621511 | Q301 | 80001989 | |||||||||||||||||||||||||||||||||
| 1600 | Hereditary Hemochromatosis (HFE), Common Variants | 81256 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 243.00 | Percent | 25.00% | KDL | $ 324.00 | 621511 | Q301 | 80001989 | |||||||||||||||||||||||||||||||||
| 6810 | Solid Tissue Tumor: Full Study | 88262 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 423.00 | Percent | 25.00% | KDL | $ 564.00 | 621511 | Q301 | 80001989 | |||||||||||||||||||||||||||||||||
| 6754 | Solid Tissue/Fibroblasts (includes POC): Full Chromosome Study reflexed to FISH | 88262 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 423.00 | Percent | 25.00% | KDL | $ 564.00 | 621511 | Q301 | 80001989 | |||||||||||||||||||||||||||||||||
| 6460 | Solid Tissue/Lymph Node | 88262 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 423.00 | Percent | 25.00% | KDL | $ 564.00 | 621511 | Q301 | 80001989 | |||||||||||||||||||||||||||||||||
| 6750 | Solid Tissue/Spleen | 88262 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 423.00 | Percent | 25.00% | KDL | $ 564.00 | 621511 | Q301 | 80001989 | |||||||||||||||||||||||||||||||||
| 6750 | Tissue Chromosome Study | 88262 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 423.00 | Percent | 25.00% | KDL | $ 564.00 | 621511 | Q301 | 80001989 | |||||||||||||||||||||||||||||||||
| 6100 | Chorionic Villus Sampling: Full Chromosome Analysis | 88262 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 423.00 | Percent | 25.00% | KDL | $ 564.00 | 621511 | Q301 | 80001992 | |||||||||||||||||||||||||||||||||
| 4460 | FLT3 ITD Mutation, Quantitative, PCR | 81246 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 80.25 | Percent | 25.00% | KDL | $ 107.00 | 621511 | Q301 | 80001993 | |||||||||||||||||||||||||||||||||
| 6242 | KDL Non-Testing Services (Cell Culture + DNA Banking) | 88233 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 478.50 | Percent | 25.00% | KDL | $ 638.00 | 621511 | Q301 | 80001993 | |||||||||||||||||||||||||||||||||
| 6242 | KDL Non-Testing Services (Cell Culture) | 88233 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 478.50 | Percent | 25.00% | KDL | $ 638.00 | 621511 | Q301 | 80001993 | |||||||||||||||||||||||||||||||||
| 8115 | CCND1 (11q13) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80001994 | |||||||||||||||||||||||||||||||||
| 8500 | C-MET/CEP7 (7q31.2) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80001994 | |||||||||||||||||||||||||||||||||
| 8105 | Cri-du-Chat (5p-) Syndrome (5p15.2) | 88273 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 168.75 | Percent | 25.00% | KDL | $ 225.00 | 621511 | Q301 | 80001994 | |||||||||||||||||||||||||||||||||
| 8125 | D13S25 (13q14.3) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80001994 | |||||||||||||||||||||||||||||||||
| 8500 | MET amp | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 121.50 | Percent | 25.00% | KDL | $ 162.00 | 621511 | Q301 | 80001994 | |||||||||||||||||||||||||||||||||
| 8774 | SS18 (18q11.2) (aka SYT) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 121.50 | Percent | 25.00% | KDL | $ 162.00 | 621511 | Q301 | 80001994 | |||||||||||||||||||||||||||||||||
| 7020 | Angelman Syndrome / Prader Willi (SNRPN/D15S10) (15q11-13) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 83.25 | Percent | 25.00% | KDL | $ 111.00 | 621511 | Q301 | 80001996 | |||||||||||||||||||||||||||||||||
| 8105 | CSF1R (5q32) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 77.25 | Percent | 25.00% | KDL | $ 103.00 | 621511 | Q301 | 80001996 | |||||||||||||||||||||||||||||||||
| 7140 | DiGeorge Syndrome (TUPLE1) (22q11.2) | 88274 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 186.75 | Percent | 25.00% | KDL | $ 249.00 | 621511 | Q301 | 80001996 | |||||||||||||||||||||||||||||||||
| 7510 | Miller Dieker Syndrome (LIS1) (17p13.3) | 88273 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 168.75 | Percent | 25.00% | KDL | $ 225.00 | 621511 | Q301 | 80001996 | |||||||||||||||||||||||||||||||||
| 7020 | Prader-Willi Syndrome (SNRPN/D15S10) (15q11-13) | 88273 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 337.50 | Percent | 25.00% | KDL | $ 450.00 | 621511 | Q301 | 80001996 | |||||||||||||||||||||||||||||||||
| 7750 | Smith-Magenis Syndrome | 88273 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 168.75 | Percent | 25.00% | KDL | $ 225.00 | 621511 | Q301 | 80001996 | |||||||||||||||||||||||||||||||||
| 8762 | SNRPN Dup(15) in autism | 88273 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 168.75 | Percent | 25.00% | KDL | $ 225.00 | 621511 | Q301 | 80001996 | |||||||||||||||||||||||||||||||||
| 7870 | Velocardiofacial Syndrome (TUPLE1) | 88273 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 168.75 | Percent | 25.00% | KDL | $ 225.00 | 621511 | Q301 | 80001996 | |||||||||||||||||||||||||||||||||
| 7900 | Williams Syndrome (ELN) (7q11.23) | 88273 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 168.75 | Percent | 25.00% | KDL | $ 225.00 | 621511 | Q301 | 80001996 | |||||||||||||||||||||||||||||||||
| 7920 | Wolf-Hirshhorn Syndrome, (WHS) (4p-) (WHSCR) (4p16.3) | 88273 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 168.75 | Percent | 25.00% | KDL | $ 225.00 | 621511 | Q301 | 80001996 | |||||||||||||||||||||||||||||||||
| 7140 | DiGeorge Syndrome (TUPLE1) (22q11.2) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 83.25 | Percent | 25.00% | KDL | $ 111.00 | 621511 | Q301 | 80001997 | |||||||||||||||||||||||||||||||||
| 8762 | SNRPN Dup(15) in autism | 88274 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 186.75 | Percent | 25.00% | KDL | $ 249.00 | 621511 | Q301 | 80001997 | |||||||||||||||||||||||||||||||||
| 7870 | Velocardiofacial Syndrome (TUPLE1) | 88274 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 186.75 | Percent | 25.00% | KDL | $ 249.00 | 621511 | Q301 | 80001997 | |||||||||||||||||||||||||||||||||
| 4375 | Erythrocytosis Panel (JAK2 V617F, reflex to JAK2 Exon 12) | 81270 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 543.75 | Percent | 25.00% | KDL | $ 725.00 | 621511 | Q301 | 80002001 | |||||||||||||||||||||||||||||||||
| 6527 | DNA Methylation Profiling | 81277 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,750.50 | Percent | 25.00% | KDL | $ 2,334.00 | 621511 | Q301 | 80002194 | |||||||||||||||||||||||||||||||||
| 6242 | KDL Non-Testing Services (Cell Culture + DNA Banking) | N/A | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 90.75 | Percent | 25.00% | KDL | $ 121.00 | 621511 | Q301 | 80002194 | |||||||||||||||||||||||||||||||||
| 8546 | 1p36/1q25 (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 541.50 | Percent | 25.00% | KDL | $ 722.00 | 621511 | Q301 | 80002978 | |||||||||||||||||||||||||||||||||
| 8050 | BCL6 (3q27) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80002978 | |||||||||||||||||||||||||||||||||
| 4150 | CEBPA Mutation Analysis | 81218 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,206.75 | Percent | 25.00% | KDL | $ 1,609.00 | 621511 | Q301 | 80002978 | |||||||||||||||||||||||||||||||||
| 8022 | D5S23/D5S21/CEN9/CEN15 | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 814.50 | Percent | 25.00% | KDL | $ 1,086.00 | 621511 | Q301 | 80002978 | |||||||||||||||||||||||||||||||||
| 7090 | IGH/CCND1 t(11;14) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 541.50 | Percent | 25.00% | KDL | $ 722.00 | 621511 | Q301 | 80002978 | |||||||||||||||||||||||||||||||||
| 8625 | PDGFRB (5q33.1) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 541.50 | Percent | 25.00% | KDL | $ 722.00 | 621511 | Q301 | 80002978 | |||||||||||||||||||||||||||||||||
| 8636 | PML/RARA t(15;17) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 541.50 | Percent | 25.00% | KDL | $ 722.00 | 621511 | Q301 | 80002978 | |||||||||||||||||||||||||||||||||
| 8692 | RB1 (13q14)/D13S319 (13q14.3) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 541.50 | Percent | 25.00% | KDL | $ 722.00 | 621511 | Q301 | 80002978 | |||||||||||||||||||||||||||||||||
| 8700 | RET (10q11.2) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 541.50 | Percent | 25.00% | KDL | $ 722.00 | 621511 | Q301 | 80002978 | |||||||||||||||||||||||||||||||||
| 6460 | Solid Tissue/Lymph Node | 88239 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 506.25 | Percent | 25.00% | KDL | $ 675.00 | 621511 | Q301 | 80003367 | |||||||||||||||||||||||||||||||||
| 6620 | Premature Chromatid Separation Analysis | 88237 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 384.00 | Percent | 25.00% | KDL | $ 512.00 | 621511 | Q301 | 80003369 | |||||||||||||||||||||||||||||||||
| 6650 | Sister Chromatid Exchange Analysis | 88230 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 260.25 | Percent | 25.00% | KDL | $ 347.00 | 621511 | Q301 | 80003370 | |||||||||||||||||||||||||||||||||
| 6650 | Sister Chromatid Exchange Analysis | 88283 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 538.50 | Percent | 25.00% | KDL | $ 718.00 | 621511 | Q301 | 80003371 | |||||||||||||||||||||||||||||||||
| 6650 | Sister Chromatid Exchange Analysis | 88285 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 245.25 | Percent | 25.00% | KDL | $ 327.00 | 621511 | Q301 | 80003372 | |||||||||||||||||||||||||||||||||
| 6750 | Solid Tissue/Spleen | 88239 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 338.25 | Percent | 25.00% | KDL | $ 451.00 | 621511 | Q301 | 80003373 | |||||||||||||||||||||||||||||||||
| 6750 | Tissue Chromosome Study | 88239 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 338.25 | Percent | 25.00% | KDL | $ 451.00 | 621511 | Q301 | 80003373 | |||||||||||||||||||||||||||||||||
| 6810 | Solid Tissue Tumor: Full Study | 88239 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 502.50 | Percent | 25.00% | KDL | $ 670.00 | 621511 | Q301 | 80003377 | |||||||||||||||||||||||||||||||||
| 8091 | CEP12 | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003378 | |||||||||||||||||||||||||||||||||
| 8274 | 1p36/1q25, 19p13/19q13 | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003379 | |||||||||||||||||||||||||||||||||
| 8546 | 1p36/1q25 | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003381 | |||||||||||||||||||||||||||||||||
| 8021 | ALL Aneuploidy | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 524.25 | Percent | 25.00% | KDL | $ 699.00 | 621511 | Q301 | 80003382 | |||||||||||||||||||||||||||||||||
| 8021 | CEP4/CEN10/CEN17 | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 524.25 | Percent | 25.00% | KDL | $ 699.00 | 621511 | Q301 | 80003382 | |||||||||||||||||||||||||||||||||
| 8022 | D5S23/D5S21/CEN9/CEN15 | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 524.25 | Percent | 25.00% | KDL | $ 699.00 | 621511 | Q301 | 80003383 | |||||||||||||||||||||||||||||||||
| 8670 | MYB (6q23)/6q21/CEN6 | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 262.50 | Percent | 25.00% | KDL | $ 350.00 | 621511 | Q301 | 80003384 | |||||||||||||||||||||||||||||||||
| 8087 | CEP8 | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003385 | |||||||||||||||||||||||||||||||||
| 4825 | Lung Cancer Panel (EGFR, ALK, ROS1) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003386 | |||||||||||||||||||||||||||||||||
| 8019 | ALK (2p23) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003387 | |||||||||||||||||||||||||||||||||
| 7014 | AML Panel (FFPE) | 88369 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 2,407.50 | Percent | 25.00% | KDL | $ 3,210.00 | 621511 | Q301 | 80003389 | |||||||||||||||||||||||||||||||||
| 7014 | AML Panel | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 7 | EA | $ 1,922.25 | Percent | 25.00% | KDL | $ 2,563.00 | 621511 | Q301 | 80003390 | |||||||||||||||||||||||||||||||||
| 8020 | RUNX1/RUNX1T1 (aka AML/ETO) t(8;21) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003391 | |||||||||||||||||||||||||||||||||
| 7018 | AneuVysion (chromosomes 13, 18, 21, X and Y) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 828.75 | Percent | 25.00% | KDL | $ 1,105.00 | 621511 | Q301 | 80003392 | |||||||||||||||||||||||||||||||||
| 1020 | Angelman Syndrome Methylation and Del/Dup | 81331 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 335.25 | Percent | 25.00% | KDL | $ 447.00 | 621511 | Q301 | 80003393 | |||||||||||||||||||||||||||||||||
| 8025 | BIRC3/MALT1 t(11;18) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003394 | |||||||||||||||||||||||||||||||||
| 8027 | ATM (11q22.3) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003395 | |||||||||||||||||||||||||||||||||
| 7040 | BCR/ABL +/- ASS t(9;22) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 20 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003396 | |||||||||||||||||||||||||||||||||
| 8050 | BCL6 (3q27) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003397 | |||||||||||||||||||||||||||||||||
| 7040 | BCR/ABL +/- ASS t(9;22) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 20 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003398 | |||||||||||||||||||||||||||||||||
| 8075 | CBFB (16q22) inv(16)/t(16;16) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003401 | |||||||||||||||||||||||||||||||||
| 8090 | CHIC2 (4q11) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003402 | |||||||||||||||||||||||||||||||||
| 1250 | Dementia Panel | 81406 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,749.75 | Percent | 25.00% | KDL | $ 2,333.00 | 621511 | Q301 | 80003403 | |||||||||||||||||||||||||||||||||
| 8092 | DDIT3 (12q13) (aka CHOP) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003404 | |||||||||||||||||||||||||||||||||
| 7100 | CLL/SLL Panel (FFPE) | 88369 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,530.00 | Percent | 25.00% | KDL | $ 2,040.00 | 621511 | Q301 | 80003405 | |||||||||||||||||||||||||||||||||
| 7100 | CLL/SLL Panel | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 21 | EA | $ 1,048.50 | Percent | 25.00% | KDL | $ 1,398.00 | 621511 | Q301 | 80003406 | |||||||||||||||||||||||||||||||||
| 8098 | MYC (8q24) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003407 | |||||||||||||||||||||||||||||||||
| 8098 | MYC (8q24) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003408 | |||||||||||||||||||||||||||||||||
| 8100 | COL1A/PDGFB t(17;22) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003409 | |||||||||||||||||||||||||||||||||
| 8105 | CSF1R (5q32) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003411 | |||||||||||||||||||||||||||||||||
| 8127 | D13S319 (13q14.3)/13q34 | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 2 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003414 | |||||||||||||||||||||||||||||||||
| 8130 | D7S486 (7q31)/CEN7 | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003415 | |||||||||||||||||||||||||||||||||
| 1260 | Dilated Cardiomyopathy Panel | 81439 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,749.75 | Percent | 25.00% | KDL | $ 2,333.00 | 621511 | Q301 | 80003417 | |||||||||||||||||||||||||||||||||
| 8175 | TCF3 (19p13.3) (aka E2A) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003418 | |||||||||||||||||||||||||||||||||
| 8180 | EGFR (7p12)/CEN7 | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003419 | |||||||||||||||||||||||||||||||||
| 1291 | Epilepsy/Seizures Panel | 81408 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,749.75 | Percent | 25.00% | KDL | $ 2,333.00 | 621511 | Q301 | 80003420 | |||||||||||||||||||||||||||||||||
| 8182 | EGR1 (5q31.1)/5p15.2 | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 3 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003421 | |||||||||||||||||||||||||||||||||
| 2875 | Exome Deletion/Duplication - Proband | 81228 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 874.50 | Percent | 25.00% | KDL | $ 1,166.00 | 621511 | Q301 | 80003423 | |||||||||||||||||||||||||||||||||
| 8200 | EWSR1 (22q12.2) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003424 | |||||||||||||||||||||||||||||||||
| 7210 | Fanconi Anemia FISH Panel | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,572.75 | Percent | 25.00% | KDL | $ 2,097.00 | 621511 | Q301 | 80003425 | |||||||||||||||||||||||||||||||||
| 8219 | FGFR1/CEP 8 amp | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003426 | |||||||||||||||||||||||||||||||||
| 8218 | FGFR1 (8p21) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003427 | |||||||||||||||||||||||||||||||||
| 8219 | FGFR1/CEP 8 amp | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003427 | |||||||||||||||||||||||||||||||||
| 1480 | Fragile X Syndrome, FMR1 | 81243 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 174.75 | Percent | 25.00% | KDL | $ 233.00 | 621511 | Q301 | 80003428 | |||||||||||||||||||||||||||||||||
| 8230 | FOX01 (13q14.11) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003429 | |||||||||||||||||||||||||||||||||
| 1490 | Genetic Aortopathy and Arteriopathy Panel | 81410 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,749.75 | Percent | 25.00% | KDL | $ 2,333.00 | 621511 | Q301 | 80003430 | |||||||||||||||||||||||||||||||||
| 8250 | FUS (16p11.2) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003431 | |||||||||||||||||||||||||||||||||
| 7270 | Glioma Panel | 88369 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,181.25 | Percent | 25.00% | KDL | $ 1,575.00 | 621511 | Q301 | 80003432 | |||||||||||||||||||||||||||||||||
| 7360 | IGH/BCL2 t(14;18) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003433 | |||||||||||||||||||||||||||||||||
| 7090 | IGH/CCND1 t(11;14) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 3 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003434 | |||||||||||||||||||||||||||||||||
| 8338 | IGH/FGFR3 t(4;14) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 5 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003435 | |||||||||||||||||||||||||||||||||
| 8340 | IGH/MAF t(14;16) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 4 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003436 | |||||||||||||||||||||||||||||||||
| 8341 | IGH/MALT1 t(14;18) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003437 | |||||||||||||||||||||||||||||||||
| 8342 | IGH/MYC t(8;14) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003438 | |||||||||||||||||||||||||||||||||
| 7020 | Angelman Syndrome / Prader Willi (SNRPN/D15S10) (15q11-13) | 88273 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 337.50 | Percent | 25.00% | KDL | $ 450.00 | 621511 | Q301 | 80003439 | |||||||||||||||||||||||||||||||||
| 6510 | Chromosome Microarray - Prenatal | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003439 | |||||||||||||||||||||||||||||||||
| 7014 | AML Panel | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 7 | EA | $ 742.50 | Percent | 25.00% | KDL | $ 990.00 | 621511 | Q301 | 80003440 | |||||||||||||||||||||||||||||||||
| 7014 | AML Panel (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 365.25 | Percent | 25.00% | KDL | $ 487.00 | 621511 | Q301 | 80003440 | |||||||||||||||||||||||||||||||||
| 8022 | AML/MDS FISH Panel | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 3 | EA | $ 945.00 | Percent | 25.00% | KDL | $ 1,260.00 | 621511 | Q301 | 80003440 | |||||||||||||||||||||||||||||||||
| 7010 | B-ALL FISH Panel | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 607.50 | Percent | 25.00% | KDL | $ 810.00 | 621511 | Q301 | 80003440 | |||||||||||||||||||||||||||||||||
| 8087 | CEP8 | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003440 | |||||||||||||||||||||||||||||||||
| 7100 | CLL/SLL Panel (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 365.25 | Percent | 25.00% | KDL | $ 487.00 | 621511 | Q301 | 80003440 | |||||||||||||||||||||||||||||||||
| 8130 | D7S486 (7q31)/CEN7 | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003440 | |||||||||||||||||||||||||||||||||
| 7450 | Diffuse Large B-cell Lymphoma Panel | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,136.25 | Percent | 25.00% | KDL | $ 1,515.00 | 621511 | Q301 | 80003440 | |||||||||||||||||||||||||||||||||
| 1460 | Fanconi Anemia Panel | 81479 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,749.75 | Percent | 25.00% | KDL | $ 2,333.00 | 621511 | Q301 | 80003440 | |||||||||||||||||||||||||||||||||
| 7190 | Hypereosinophilic Syndrome (HES) / Chronic Myelomonocytic Leukemia (CMML) / Myeloproliferative Neoplasms (MPN) FISH Panel | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 4 | EA | $ 1,398.00 | Percent | 25.00% | KDL | $ 1,864.00 | 621511 | Q301 | 80003440 | |||||||||||||||||||||||||||||||||
| 7454 | Marginal Zone Lymphoma Panel | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 3 | EA | $ 699.00 | Percent | 25.00% | KDL | $ 932.00 | 621511 | Q301 | 80003440 | |||||||||||||||||||||||||||||||||
| 7500 | MDS Panel | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 4 | EA | $ 1,223.25 | Percent | 25.00% | KDL | $ 1,631.00 | 621511 | Q301 | 80003440 | |||||||||||||||||||||||||||||||||
| 7520 | Multiple Myeloma Panel | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 19 | EA | $ 1,747.50 | Percent | 25.00% | KDL | $ 2,330.00 | 621511 | Q301 | 80003440 | |||||||||||||||||||||||||||||||||
| 8178 | T-ALL FISH Panel | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,048.50 | Percent | 25.00% | KDL | $ 1,398.00 | 621511 | Q301 | 80003440 | |||||||||||||||||||||||||||||||||
| 8546 | 1p36/1q25 | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8019 | ALK (2p23) (FFPE) | 88369 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 2264 | Autosomal Dominant Osteogenesis Imperfecta Panel (ADOI) | 81408 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,749.75 | Percent | 25.00% | KDL | $ 2,333.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8040 | BCL2 (18q21.3) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8050 | BCL6 (3q27) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 4020 | BCR-ABL Kinase Domain Mutations (Sequencing) | 81170 | Yes | Base | 7/1/26 | 6/30/27 | 2 | EA | $ 972.00 | Percent | 25.00% | KDL | $ 1,296.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 6054 | Blood: High Resolution Chromosome Study reflexed to FISH | 88289 | Yes | Base | 7/1/26 | 6/30/27 | 4 | EA | $ 84.00 | Percent | 25.00% | KDL | $ 112.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 4615 | CBFB::MYH11 Digital PCR | 81401 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 789.75 | Percent | 25.00% | KDL | $ 1,053.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8615 | CDKN2A (9p21)/CEN9 | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8615 | CDKN2A (9p21)/CEN9 | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8080 | CEP X and CEP Y FISH | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8021 | CEP4/CEN10/CEN17 | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 814.50 | Percent | 25.00% | KDL | $ 1,086.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 1035 | Charcot-Marie-Tooth Syndrome Panel | 81448 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,749.75 | Percent | 25.00% | KDL | $ 2,333.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 1290 | Childhood Epilepsy Panel | 81407 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,749.75 | Percent | 25.00% | KDL | $ 2,333.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8500 | C-MET/CEP7 (7q31.2) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 1153 | Comprehensive Arrhythmias Panel | 81413 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,749.75 | Percent | 25.00% | KDL | $ 2,333.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 4133 | CXCR4 Mutation Testing | 81479 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 500.25 | Percent | 25.00% | KDL | $ 667.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8127 | D13S319 (13q14.3)/13q34 | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 2 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8129 | D20S108 (20q12)/20p tel | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8129 | D20S108 (20q12)/20p tel | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8092 | DDIT3 (12q13) (aka CHOP) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8092 | DDIT3 (12q13) (aka CHOP) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8180 | EGFR (7p12)/CEN7 (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8182 | EGR1 (5q31.1)/5p15.2 (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8795 | ETV6 (12p13) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8794 | ETV6/RUNX1 t(12;21) (TEL/AML1) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8200 | EWSR1 (22q12.2) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8218 | FGFR1 (8p21) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8219 | FGFR1/CEP 8 amp (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8230 | FOX01 (13q14.11) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8250 | FUS (16p11.2) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 7359 | IGH (14q32) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 7360 | IGH/BCL2 t(14;18) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 7090 | IGH/CCND1 t(11;14) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 3 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8338 | IGH/FGFR3 t(4;14) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 5 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8340 | IGH/MAF t(14;16) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 4 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8341 | IGH/MALT1 t(14;18) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8342 | IGH/MYC t(8;14) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8395 | Kallman Syndrome (KAL) (Xp22.3) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8490 | MALT1 (18q21) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8498 | MDM2 (12q15) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8500 | MET amp | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8503 | MLL (11q23.3) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8670 | MYB (6q23)/6q21/CEN6 | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 612.00 | Percent | 25.00% | KDL | $ 816.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8098 | MYC (8q24) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8580 | N-MYC (2p24) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8625 | PDGFRB (5q33.1) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8636 | PML/RARA t(15;17) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 4 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8642 | PTEN (10q23)/CEN10 | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8692 | RB1 (13q14)/D13S319 (13q14.3) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 2 | EA | $ 612.00 | Percent | 25.00% | KDL | $ 816.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8692 | RB1/D13S319 (13q14) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 612.00 | Percent | 25.00% | KDL | $ 816.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8020 | RUNX1/RUNX1T1 (aka AML/ETO) t(8;21) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8756 | SHOX-related Haploinsufficiency Disorders, SHOX (Xp22.33) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8772 | SRY-related disorders of sex development, SRY (Yp11.3) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8774 | SS18 (18q11.2) (aka SYT) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8775 | Steroid Sulfatase (STS) (Xp22.3) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8175 | TCF3 (19p13.3) (aka E2A) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8618 | TP53 (17p13)/CEN17 | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8410 | TRA/D (14q11.1-11.2) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003441 | |||||||||||||||||||||||||||||||||
| 8395 | Kallman Syndrome (KAL) (Xp22.3) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 120.75 | Percent | 25.00% | KDL | $ 161.00 | 621511 | Q301 | 80003442 | |||||||||||||||||||||||||||||||||
| 7450 | Diffuse Large B-cell Lymphoma Panel (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 393.75 | Percent | 25.00% | KDL | $ 525.00 | 621511 | Q301 | 80003443 | |||||||||||||||||||||||||||||||||
| 7454 | Marginal Zone Lymphoma Panel (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 365.25 | Percent | 25.00% | KDL | $ 487.00 | 621511 | Q301 | 80003444 | |||||||||||||||||||||||||||||||||
| 7454 | Marginal Zone Lymphoma Panel | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 3 | EA | $ 561.00 | Percent | 25.00% | KDL | $ 748.00 | 621511 | Q301 | 80003445 | |||||||||||||||||||||||||||||||||
| 7450 | Diffuse Large B-cell Lymphoma Panel (FFPE) | 88369 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,575.00 | Percent | 25.00% | KDL | $ 2,100.00 | 621511 | Q301 | 80003446 | |||||||||||||||||||||||||||||||||
| 8490 | MALT1 (18q21) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003447 | |||||||||||||||||||||||||||||||||
| 8498 | MDM2 (12q15) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003448 | |||||||||||||||||||||||||||||||||
| 8498 | MDM2 (12q15) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003449 | |||||||||||||||||||||||||||||||||
| 7500 | MDS Panel | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 4 | EA | $ 981.75 | Percent | 25.00% | KDL | $ 1,309.00 | 621511 | Q301 | 80003450 | |||||||||||||||||||||||||||||||||
| 8100 | COL1A/PDGFB t(17;22) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003451 | |||||||||||||||||||||||||||||||||
| 8500 | MET amp (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003451 | |||||||||||||||||||||||||||||||||
| 7510 | Miller Dieker Syndrome (LIS1) (17p13.3) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 115.50 | Percent | 25.00% | KDL | $ 154.00 | 621511 | Q301 | 80003453 | |||||||||||||||||||||||||||||||||
| 8503 | MLL (11q23.3) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003454 | |||||||||||||||||||||||||||||||||
| 7520 | Multiple Myeloma Panel | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 19 | EA | $ 675.00 | Percent | 25.00% | KDL | $ 900.00 | 621511 | Q301 | 80003455 | |||||||||||||||||||||||||||||||||
| 7520 | Multiple Myeloma Panel (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 365.25 | Percent | 25.00% | KDL | $ 487.00 | 621511 | Q301 | 80003456 | |||||||||||||||||||||||||||||||||
| 8580 | N-MYC (2p24) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003457 | |||||||||||||||||||||||||||||||||
| 8580 | N-MYC (2p24) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003458 | |||||||||||||||||||||||||||||||||
| 8615 | CDKN2A (9p21)/CEN9 (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 541.50 | Percent | 25.00% | KDL | $ 722.00 | 621511 | Q301 | 80003459 | |||||||||||||||||||||||||||||||||
| 8618 | TP53 (17p13)/CEN17 | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003460 | |||||||||||||||||||||||||||||||||
| 8625 | PDGFRB (5q33.1) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003461 | |||||||||||||||||||||||||||||||||
| 8636 | PML/RARA t(15;17) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 4 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003462 | |||||||||||||||||||||||||||||||||
| 7020 | Prader-Willi Syndrome (SNRPN/D15S10) (15q11-13) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 83.25 | Percent | 25.00% | KDL | $ 111.00 | 621511 | Q301 | 80003463 | |||||||||||||||||||||||||||||||||
| 8642 | PTEN (10q23)/CEN10 (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003464 | |||||||||||||||||||||||||||||||||
| 8642 | PTEN (10q23)/CEN10 | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003465 | |||||||||||||||||||||||||||||||||
| 8692 | RB1 (13q14)/D13S319 (13q14.3) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 2 | EA | $ 262.50 | Percent | 25.00% | KDL | $ 350.00 | 621511 | Q301 | 80003466 | |||||||||||||||||||||||||||||||||
| 8692 | RB1/D13S319 (13q14) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 262.50 | Percent | 25.00% | KDL | $ 350.00 | 621511 | Q301 | 80003466 | |||||||||||||||||||||||||||||||||
| 8756 | SHOX-related Haploinsufficiency Disorders, SHOX (Xp22.33) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003467 | |||||||||||||||||||||||||||||||||
| 7750 | Smith-Magenis Syndrome | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 83.25 | Percent | 25.00% | KDL | $ 111.00 | 621511 | Q301 | 80003468 | |||||||||||||||||||||||||||||||||
| 8762 | SNRPN Dup(15) in autism | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 83.25 | Percent | 25.00% | KDL | $ 111.00 | 621511 | Q301 | 80003469 | |||||||||||||||||||||||||||||||||
| 8772 | SRY-related disorders of sex development, SRY (Yp11.3) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003470 | |||||||||||||||||||||||||||||||||
| 8775 | Steroid Sulfatase (STS) (Xp22.3) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003471 | |||||||||||||||||||||||||||||||||
| 8200 | EWSR1 (22q12.2) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003474 | |||||||||||||||||||||||||||||||||
| 7870 | Velocardiofacial Syndrome (TUPLE1) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 83.25 | Percent | 25.00% | KDL | $ 111.00 | 621511 | Q301 | 80003475 | |||||||||||||||||||||||||||||||||
| 7900 | Williams Syndrome (ELN) (7q11.23) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 83.25 | Percent | 25.00% | KDL | $ 111.00 | 621511 | Q301 | 80003476 | |||||||||||||||||||||||||||||||||
| 7920 | Wolf-Hirshhorn Syndrome, (WHS) (4p-) (WHSCR) (4p16.3) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 83.25 | Percent | 25.00% | KDL | $ 111.00 | 621511 | Q301 | 80003477 | |||||||||||||||||||||||||||||||||
| 6510 | Chromosome Microarray - Prenatal | 81229 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,157.25 | Percent | 25.00% | KDL | $ 1,543.00 | 621511 | Q301 | 80003478 | |||||||||||||||||||||||||||||||||
| 8091 | CEP12 | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003479 | |||||||||||||||||||||||||||||||||
| 1004 | Agenesis of the Corpus Callosum Panel | 81407 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,749.75 | Percent | 25.00% | KDL | $ 2,333.00 | 621511 | Q301 | 80003551 | |||||||||||||||||||||||||||||||||
| 8338 | IGH/FGFR3 t(4;14) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003555 | |||||||||||||||||||||||||||||||||
| 7360 | IGH/BCL2 t(14;18) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003556 | |||||||||||||||||||||||||||||||||
| 4360 | EGFR Mutation Analysis (exons 18-21) | 81235 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 874.50 | Percent | 25.00% | KDL | $ 1,166.00 | 621511 | Q301 | 80003557 | |||||||||||||||||||||||||||||||||
| 8410 | TRA/D (14q11.1-11.2) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003558 | |||||||||||||||||||||||||||||||||
| 8040 | BCL2 (18q21.3) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 541.50 | Percent | 25.00% | KDL | $ 722.00 | 621511 | Q301 | 80003561 | |||||||||||||||||||||||||||||||||
| 7359 | IGH (14q32) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003563 | |||||||||||||||||||||||||||||||||
| 8794 | ETV6/RUNX1 t(12;21) (TEL/AML1) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003564 | |||||||||||||||||||||||||||||||||
| 8129 | D20S108 (20q12)/20p tel (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 541.50 | Percent | 25.00% | KDL | $ 722.00 | 621511 | Q301 | 80003565 | |||||||||||||||||||||||||||||||||
| 7600 | GeneTrails NSCLC Panel FISH | 88369 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,181.25 | Percent | 25.00% | KDL | $ 1,575.00 | 621511 | Q301 | 80003576 | |||||||||||||||||||||||||||||||||
| 4825 | Lung Cancer Panel (EGFR, ALK, ROS1) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003609 | |||||||||||||||||||||||||||||||||
| 8720 | ROS1 (6q22) (FFPE) | 88368 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 546.75 | Percent | 25.00% | KDL | $ 729.00 | 621511 | Q301 | 80003609 | |||||||||||||||||||||||||||||||||
| 1222 | Cystic Fibrosis, CFTR Sequencing | 81223 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 874.50 | Percent | 25.00% | KDL | $ 1,166.00 | 621511 | Q301 | 80003638 | |||||||||||||||||||||||||||||||||
| 1230 | Known Familial Variant - Cystic Fibrosis, CFTR | 81221 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 222.00 | Percent | 25.00% | KDL | $ 296.00 | 621511 | Q301 | 80003639 | |||||||||||||||||||||||||||||||||
| 4070 | B-Cell (IgH and Ig-kappa) Gene Rearrangement (Clonality) | 81264 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 685.50 | Percent | 25.00% | KDL | $ 914.00 | 621511 | Q301 | 80003641 | |||||||||||||||||||||||||||||||||
| 4072 | B-Cell IGK Gene Rearrangement | 81264 | Yes | Base | 7/1/26 | 6/30/27 | 6 | EA | $ 685.50 | Percent | 25.00% | KDL | $ 914.00 | 621511 | Q301 | 80003641 | |||||||||||||||||||||||||||||||||
| 4071 | B-Cell IGH Gene Rearrangement | 81261 | Yes | Base | 7/1/26 | 6/30/27 | 6 | EA | $ 685.50 | Percent | 25.00% | KDL | $ 914.00 | 621511 | Q301 | 80003642 | |||||||||||||||||||||||||||||||||
| 8040 | BCL2 (18q21.3) | 88275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 306.00 | Percent | 25.00% | KDL | $ 408.00 | 621511 | Q301 | 80003642 | |||||||||||||||||||||||||||||||||
| 4080 | BCR-ABL RNA Quantitation, PCR - Major/Minor Breakpoints | 81206 | Yes | Base | 7/1/26 | 6/30/27 | 129 | EA | $ 510.00 | Percent | 25.00% | KDL | $ 680.00 | 621511 | Q301 | 80003643 | |||||||||||||||||||||||||||||||||
| 4080 | BCR-ABL RNA Quantitation, PCR - Major/Minor Breakpoints | 81207 | Yes | Base | 7/1/26 | 6/30/27 | 2 | EA | $ 472.50 | Percent | 25.00% | KDL | $ 630.00 | 621511 | Q301 | 80003643 | |||||||||||||||||||||||||||||||||
| 8025 | BIRC3/MALT1 t(11;18) | 88271 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 131.25 | Percent | 25.00% | KDL | $ 175.00 | 621511 | Q301 | 80003644 | |||||||||||||||||||||||||||||||||
| 4525 | GNAQ and GNA11 Mutation Analysis | 81479 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 225.00 | Percent | 25.00% | KDL | $ 300.00 | 621511 | Q301 | 80003645 | |||||||||||||||||||||||||||||||||
| 4810 | H3F3A Mutation Analysis | 81479 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 408.00 | Percent | 25.00% | KDL | $ 544.00 | 621511 | Q301 | 80003646 | |||||||||||||||||||||||||||||||||
| 4650 | IDH1 & IDH2 Mutation Analysis | 81403 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 468.00 | Percent | 25.00% | KDL | $ 624.00 | 621511 | Q301 | 80003647 | |||||||||||||||||||||||||||||||||
| 4650 | IDH1 & IDH2 Mutation Analysis | 81403 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 468.00 | Percent | 25.00% | KDL | $ 624.00 | 621511 | Q301 | 80003648 | |||||||||||||||||||||||||||||||||
| 4224 | GeneTrails Colon Mutation Panel (KRAS, BRAF, NRAS) | 81403 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 385.50 | Percent | 25.00% | KDL | $ 514.00 | 621511 | Q301 | 80003649 | |||||||||||||||||||||||||||||||||
| 4800 | KRAS Mutation Analysis (exons 1, 2) | 81275 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 255.00 | Percent | 25.00% | KDL | $ 340.00 | 621511 | Q301 | 80003649 | |||||||||||||||||||||||||||||||||
| 4224 | GeneTrails Colon Mutation Panel (KRAS, BRAF, NRAS) | 81479 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 43.50 | Percent | 25.00% | KDL | $ 58.00 | 621511 | Q301 | 80003650 | |||||||||||||||||||||||||||||||||
| 8340 | IGH/MAF t(14;16) (FFPE) | 81403 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 385.50 | Percent | 25.00% | KDL | $ 514.00 | 621511 | Q301 | 80003650 | |||||||||||||||||||||||||||||||||
| 4800 | KRAS Mutation Analysis (exons 1, 2) | 81403 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 385.50 | Percent | 25.00% | KDL | $ 514.00 | 621511 | Q301 | 80003650 | |||||||||||||||||||||||||||||||||
| 5010 | MPL Mutation Analysis | 81403 | Yes | Base | 7/1/26 | 6/30/27 | 11 | EA | $ 385.50 | Percent | 25.00% | KDL | $ 514.00 | 621511 | Q301 | 80003652 | |||||||||||||||||||||||||||||||||
| 4376 | Thrombocytosis Panel (JAK2 V617F, reflex to Calreticulin, reflex to MPL) | 81403 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 385.50 | Percent | 25.00% | KDL | $ 514.00 | 621511 | Q301 | 80003652 | |||||||||||||||||||||||||||||||||
| 5300 | PML-RARA Quantitative RT-PCR | 81315 | Yes | Base | 7/1/26 | 6/30/27 | 4 | EA | $ 568.50 | Percent | 25.00% | KDL | $ 758.00 | 621511 | Q301 | 80003653 | |||||||||||||||||||||||||||||||||
| 5590 | T and B-Cell Gene Rearrangement (B-Cell IGH and IGK, T-Cell Gamma and Beta Clonality) | 81340 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 432.75 | Percent | 25.00% | KDL | $ 577.00 | 621511 | Q301 | 80003655 | |||||||||||||||||||||||||||||||||
| 5590 | T and B-Cell Gene Rearrangement (B-Cell IGH and IGK, T-Cell Gamma and Beta Clonality) | 81342 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,162.50 | Percent | 25.00% | KDL | $ 1,550.00 | 621511 | Q301 | 80003656 | |||||||||||||||||||||||||||||||||
| 5590 | T and B-Cell Gene Rearrangement (B-Cell IGH and IGK, T-Cell Gamma and Beta Clonality) | 81261 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 260.25 | Percent | 25.00% | KDL | $ 347.00 | 621511 | Q301 | 80003657 | |||||||||||||||||||||||||||||||||
| 5590 | T and B-Cell Gene Rearrangement (B-Cell IGH and IGK, T-Cell Gamma and Beta Clonality) | 81264 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 210.00 | Percent | 25.00% | KDL | $ 280.00 | 621511 | Q301 | 80003658 | |||||||||||||||||||||||||||||||||
| 5592B | T-Cell Gene Rearrangement (Clonality) - BETA by PCR | 81340 | Yes | Base | 7/1/26 | 6/30/27 | 13 | EA | $ 562.50 | Percent | 25.00% | KDL | $ 750.00 | 621511 | Q301 | 80003659 | |||||||||||||||||||||||||||||||||
| 5592G | T-Cell Gene Rearrangement (Clonality) - GAMMA by NGS | 81342 | Yes | Base | 7/1/26 | 6/30/27 | 13 | EA | $ 1,162.50 | Percent | 25.00% | KDL | $ 1,550.00 | 621511 | Q301 | 80003660 | |||||||||||||||||||||||||||||||||
| 1224 | Cystic Fibrosis, CFTR Sequencing and Del/Dup | 81223 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 874.50 | Percent | 25.00% | KDL | $ 1,166.00 | 621511 | Q301 | 80003661 | |||||||||||||||||||||||||||||||||
| 1224 | Cystic Fibrosis, CFTR Sequencing and Del/Dup | 81222 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 437.25 | Percent | 25.00% | KDL | $ 583.00 | 621511 | Q301 | 80003661 | |||||||||||||||||||||||||||||||||
| 1450 | FANCA Sequencing and Del/Dup | 81479 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,312.50 | Percent | 25.00% | KDL | $ 1,750.00 | 621511 | Q301 | 80003665 | |||||||||||||||||||||||||||||||||
| 1452 | FANCC Sequencing | 81479 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,312.50 | Percent | 25.00% | KDL | $ 1,750.00 | 621511 | Q301 | 80003665 | |||||||||||||||||||||||||||||||||
| 1682 | Infantile Neuroaxonal Dystrophy (INAD), PLA2G6, Sequencing | 81479 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,312.50 | Percent | 25.00% | KDL | $ 1,750.00 | 621511 | Q301 | 80003667 | |||||||||||||||||||||||||||||||||
| 1680 | Infantile Neuroaxonal Dystrophy (INAD), PLA2G6, Sequencing and Del/Dup | 81479 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,312.50 | Percent | 25.00% | KDL | $ 1,750.00 | 621511 | Q301 | 80003667 | |||||||||||||||||||||||||||||||||
| 2231 | Pantothenate Kinase-Associated Neurodegeneration (PKAN), Sequencing | 81479 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,312.50 | Percent | 25.00% | KDL | $ 1,750.00 | 621511 | Q301 | 80003669 | |||||||||||||||||||||||||||||||||
| 2230 | Pantothenate Kinase-Associated Neurodegeneration (PKAN), Sequencing and Del/Dup | 81479 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,312.50 | Percent | 25.00% | KDL | $ 1,750.00 | 621511 | Q301 | 80003669 | |||||||||||||||||||||||||||||||||
| 2030 | MLH1 Sequencing and Del/Dup | 81292 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,312.50 | Percent | 25.00% | KDL | $ 1,750.00 | 621511 | Q301 | 80003683 | |||||||||||||||||||||||||||||||||
| 2402 | Rett Syndrome (RTT) - MeCP2 Sequencing and Del/Dup | 81302 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 1,312.50 | Percent | 25.00% | KDL | $ 1,750.00 | 621511 | Q301 | 80003689 | |||||||||||||||||||||||||||||||||
| 2402 | Rett Syndrome (RTT) - MeCP2 Sequencing and Del/Dup | 81304 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 437.25 | Percent | 25.00% | KDL | $ 583.00 | 621511 | Q301 | 80003690 | |||||||||||||||||||||||||||||||||
| 4386 | Post-Transplant Engraftment (1st Post Transplant PTE), Add-on Charges | 81265 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 512.25 | Percent | 25.00% | KDL | $ 683.00 | 621511 | Q301 | 80003691 | |||||||||||||||||||||||||||||||||
| 4900 | Melanoma Panel (BRAF, NRAS and cKIT Mutation Analysis) | 81210 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 532.50 | Percent | 25.00% | KDL | $ 710.00 | 621511 | Q301 | 80003723 | |||||||||||||||||||||||||||||||||
| 4900 | Melanoma Panel (BRAF, NRAS and cKIT Mutation Analysis) | 81404 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 534.00 | Percent | 25.00% | KDL | $ 712.00 | 621511 | Q301 | 80003724 | |||||||||||||||||||||||||||||||||
| 4900 | Melanoma Panel (BRAF, NRAS and cKIT Mutation Analysis) | 81404 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 534.00 | Percent | 25.00% | KDL | $ 712.00 | 621511 | Q301 | 80003725 | |||||||||||||||||||||||||||||||||
| 1226 | Cystic Fibrosis, CFTR Del/Dup | 81222 | Yes | Base | 7/1/26 | 6/30/27 | 1 | EA | $ 437.25 | Percent | 25.00% | KDL | $ 583.00 | 621511 | Q301 | 80003920 |
This is the start of the file's text. The full file is on GovTribe.
File details come from the government source that posted it. Updated .